Novo Nordisk has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Carmel, Indiana. Financial terms were not disclosed.

Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of drug candidates for treating diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US.

The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.

Source: Novo Nordisk